New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. PharmaZee is a telehealth platform that facilitates access to prescription evaluation through licensed physicians. Certain prescriptions provided through the platform may involve compounded medications prepared by licensed pharmacies. This content does not diagnose, treat, cure, or prevent ...

BELVIDERE, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced that it will participate in ECRM’s Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session, taking place February 10–12, 2026, at the Hyatt Regency Chicago O’Hare in Rosemont, Illinois. ECRM’s Total Wellness: GLP-1, Weight M ...

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has intensified following their latest fourth-quarter earnings reports. Novo Nordisk initially dominated the space with its semaglutide-based drugs, Ozempic for diabetes and Wegovy for obesity, securing a strong foothold in both markets. However, Eli Lilly has since pulled ahead with tirzepatide — marketed as Mounjaro for diabetes and Zepbound for weight loss. The drug's dual GLP- 1/GIP receptor m ...

VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this interim analysis, animals treated with a novel semaglutide/CPP topical formulation demonstrated reduced blood glucose following an oral glucose challenge compa ...

Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita’s potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6- ...

Core Insights - Genentech announced positive topline results from a Phase II clinical trial of CT-388, a dual GLP-1/GIP receptor agonist for obesity treatment, showing significant weight loss without reaching a plateau at 48 weeks [1][2][3] Company Overview - Genentech, a member of the Roche Group, is a leading biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions [8] Clinical Trial Results - The Phase II trial (CT388-103) involved 469 participants and demonstrated a placebo-adjusted weight loss of 22.5% for the efficacy estimand and 18.3% for the treatment-regimen estimand at the 24 mg dose [1][6] - At week 48, 95.7% of participants treated with CT-388 achieved at least a 5% weight loss, with 87% achieving 10%, 47.8% achieving 20%, and 26.1% achieving 30% [1] - Among pre-diabetic participants, 73% achieved normal blood glucose levels compared to 7.5% in the placebo group [1] Safety and Tolerability - The treatment was well-tolerated, with mild-to-moderate gastrointestinal-related adverse events and a low discontinuation rate due to adverse events (5.9% in CT-388 arms vs. 1.3% in placebo) [2] Future Development - Genentech has fast-tracked CT-388 and is advancing to Phase III trials, with additional studies evaluating its efficacy in participants with obesity and type 2 diabetes [5] - The Phase III clinical trial program (Enith1 and Enith2) is expected to start this quarter [5] Industry Context - Obesity is a significant global health risk, with projections indicating over four billion people will be living with excess weight or obesity by 2035, increasing the burden on healthcare systems [4]

Core Insights - Ascletis Pharma Inc. has selected ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development, with an Investigational New Drug Application (IND) submission to the FDA expected in Q2 2026 [2][5]. Group 1: Product Development - ASC37 has an average observed half-life of approximately 17 days in non-human primate studies, which is 7-fold longer than retatrutide, supporting once-monthly subcutaneous dosing [1][4]. - The in vitro activity of ASC37 is approximately 5-fold, 4-fold, and 4-fold more potent than retatrutide for GLP-1R, GIPR, and GCGR, respectively [1][3]. - ASC37 is engineered for a longer half-life compared to retatrutide, allowing for a subcutaneous injection volume of one milliliter or less, which also provides manufacturing scalability advantages [3][4]. Group 2: Clinical Strategy - The company plans to initiate a Phase I study for ASC37 in the second half of 2026, as part of its strategy to enhance treatment options for obesity [5]. - ASC37 is being developed both as a monotherapy and in combination with ASC36, another peptide agonist, to address cardio-metabolic diseases including obesity and diabetes [5]. Group 3: Technological Innovation - Ascletis utilizes its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies to design and optimize multiple once-monthly subcutaneous ultra-long-acting peptides [6][8]. - The ULAP technology allows for precise control over the release of peptides, improving clinical outcomes by reducing peak-to-trough ratios [6].

VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into fu ...

Core Insights - The analyst has over a decade of experience researching various industries, including commodities like oil, natural gas, gold, and copper, as well as technology companies such as Google and Nokia, and emerging market stocks [1] Group 1: Company Focus - The analyst has a particular interest in covering metals and mining stocks, while also being comfortable with other sectors such as consumer discretionary, consumer staples, REITs, and utilities [1] Group 2: Research Methodology - The transition from a personal blog to a value investing-focused YouTube channel has allowed the analyst to research hundreds of different companies, enhancing the quality of content provided to readers [1]

Company Overview - Global Partners LP is a leading midstream energy partnership involved in fuel distribution, storage, and retail operations, optimizing margins through integrated supply, logistics, and retailing across multiple channels [7] - The company offers a variety of products including gasoline, distillates, renewable fuels, crude oil, and propane, operating a network of gasoline stations and convenience stores primarily in the Northeastern United States [7] Financial Metrics - The company reported a total revenue of $18.10 billion and a net income of $71.54 million for the trailing twelve months (TTM) [4] - The dividend yield stands at 6.95%, with a one-year price change of -15.42% as of January 12, 2025 [4] Insider Transactions - Global GP LLC, the general partner of Global Partners LP, purchased 3,917 common units in open-market transactions on December 5 and December 8, 2025, for approximately $176,892, with a weighted average purchase price of $45.16 per unit [2][6] - Following these transactions, the direct holdings of Global GP LLC increased to 215,988 units, valued at approximately $9.75 million [2][6] - The purchases were made to fulfill obligations under the Long-Term Incentive Plan, indicating that these transactions are not strategic but rather routine [6][8] Market Performance - The stock of Global Partners LP has experienced a decline of approximately 11.30% in 2025, marking its worst year since 2020 [10] - Despite the recent downturn, the company has consistently raised dividends every quarter since Q3 FY 2021, making it a potential option for investors seeking high-dividend stocks in the gasoline industry [10]